Recombinant multi-species AKT/AKT1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine AKT/AKT1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes one of the three members of the human AKT serine-threonine protein kinase family which are often referred to as protein kinase B alpha, beta, and gamma. These highly similar AKT proteins all have an N-terminal pleckstrin homology domain, a serine/threonine-specific kinase domain and a C-terminal regulatory domain. These proteins are phosphorylated by phosphoinositide 3-kinase (PI3K). AKT/PI3K forms a key component of many signalling pathways that involve the binding of membrane-bound ligands such as receptor tyrosine kinases, G-protein coupled receptors, and integrin-linked kinase. These AKT proteins therefore regulate a wide variety of cellular functions including cell proliferation, survival, metabolism, and angiogenesis in both normal and malignant cells. AKT proteins are recruited to the cell membrane by phosphatidylinositol 3,4,5-trisphosphate (PIP3) after phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) by PI3K. Subsequent phosphorylation of both threonine residue 308 and serine residue 473 is required for full activation of the AKT1 protein encoded by this gene. Phosphorylation of additional residues also occurs, for example, in response to insulin growth factor-1 and epidermal growth factor. Protein phosphatases act as negative regulators of AKT proteins by dephosphorylating AKT or PIP3. The PI3K/AKT signalling pathway is crucial for tumor cell survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating AKT1 which then phosphorylates and inactivates components of the apoptotic machinery. AKT proteins also participate in the mammalian target of rapamycin (mTOR) signalling pathway which controls the assembly of the eukaryotic translation initiation factor 4F (eIF4E) complex and this pathway, in addition to responding to extracellular signals from growth factors and cytokines, is disregulated in many cancers. Mutations in this gene are associated with multiple types of cancer and excessive tissue growth including Proteus syndrome and Cowden syndrome 6, and breast, colorectal, and ovarian cancers. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2020]
The Alternative Names of target: AKT,AKT1,Akt,Akt1,LTR-akt,PKB,PKB-ALPHA,PKB/Akt,PKBalpha,PRKBA,Protein kinase B (PKB),Protein kinase B alpha (PKB alpha),Proto-oncogene c-Akt,RAC,RAC-ALPHA,RAC-PK-alpha,RAC-alpha serine/threonine-protein kinase,Rac

Target products collectionGo to AKT/AKT1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-T67619-Ag-1/ GM-Tg-hg-T67619-Ag-2 Human AKT/AKT1 protein Human
GM-Tg-rg-T67619-Ag-1/ GM-Tg-rg-T67619-Ag-2 Rat AKT/AKT1 protein Rat
GM-Tg-mg-T67619-Ag-1/ GM-Tg-mg-T67619-Ag-2 Mouse AKT/AKT1 protein Mouse
GM-Tg-cynog-T67619-Ag-1/ GM-Tg-cynog-T67619-Ag-2 Cynomolgus/Rhesus macaque AKT/AKT1 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-T67619-Ag-1/ GM-Tg-felg-T67619-Ag-2 Feline AKT/AKT1 protein Feline
GM-Tg-cang-T67619-Ag-1/ GM-Tg-cang-T67619-Ag-2 Canine AKT/AKT1 protein Canine
GM-Tg-bovg-T67619-Ag-1/ GM-Tg-bovg-T67619-Ag-2 Bovine AKT/AKT1 protein Bovine
GM-Tg-equg-T67619-Ag-1/ GM-Tg-equg-T67619-Ag-2 Equine AKT/AKT1 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-T67619-Ag-1/ GM-Tg-hg-T67619-Ag-2; GM-Tg-rg-T67619-Ag-1/ GM-Tg-rg-T67619-Ag-2;
GM-Tg-mg-T67619-Ag-1/ GM-Tg-mg-T67619-Ag-2; GM-Tg-cynog-T67619-Ag-1/ GM-Tg-cynog-T67619-Ag-2;
GM-Tg-felg-T67619-Ag-1/ GM-Tg-felg-T67619-Ag-2; GM-Tg-cang-T67619-Ag-1/ GM-Tg-cang-T67619-Ag-2;
GM-Tg-bovg-T67619-Ag-1/ GM-Tg-bovg-T67619-Ag-2; GM-Tg-equg-T67619-Ag-1/ GM-Tg-equg-T67619-Ag-2
Products Name AKT/AKT1 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name AKT/AKT1
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine AKT/AKT1 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.